Dana-Farber/Harvard Cancer Centeris the largest National Cancer Institute (NCI) designated Comprehensive Cancer Center in the nation. Founded in 1998, DF/HCC is an inter-institutional research enterprise that unites all of the cancer research efforts of the Harvard affiliated community. The primary goal of the Cancer Center is to encourage and promote collaborative interactions and translational research that will lead to new approaches to cancer prevention, diagnosis, and treatment.
DF/HCC’s members pool their extensive experience and acclaimed expertise in all aspects of cancer research. They carry out their research in disease site- and discipline-based research programs that cross both institutional and scientific boundaries.
DF/HCC is one of just 39 NCI designated Comprehensive Cancer Centers. Its members hail from the following institutions: Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Children's Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, and Massachusetts General Hospital. [1]
References
- ^ "NCI Cancer Centers Program". http://cancercenters.cancer.gov/cancer_centers/dfhcc.html. Retrieved on 2007-06-07.
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
